T Yoshida1,2, H Kinoshita2, H Taniguchi2, M Yanishi2, M Sugi2, T Matsuda3. 1. Department of Urology and Andrology, Kori Hospital, Kansai Medical University, 8-45 Kori Hondori cyo, Neyagawa, Osaka, 572-8551, Japan. 2. Department of Urology and Andrology, Kansai Medical University Hospital, Hirakata, 2-3-1 Shin-machi, Hirakata, Osaka, 573-1191, Japan. 3. Department of Urology and Andrology, Kansai Medical University Hospital, Hirakata, 2-3-1 Shin-machi, Hirakata, Osaka, 573-1191, Japan. matsudat@takii.kmu.ac.jp.
Abstract
There is still a lack of evidence that minodronate or denosumab prevents bone loss due to androgen deprivation therapy (ADT) in non-Western patients. This study showed that both drugs significantly improved lumbar spine and total hip bone mineral density in Asian men with prostate cancer who received ADT. INTRODUCTION: To evaluate whether monthly oral minodronate or semiannual subcutaneous injection of denosumab improves bone mineral density (BMD) in Asian men with prostate cancer (PCa) receiving ADT. METHODS: A multicenter, open-label, randomized, controlled study including patients with hormone-sensitive PCa without bone metastasis receiving ADT was performed. Patients were randomized (1:1:1) to minodronate, denosumab, or no agent control groups. The primary end point was the mean percentage change in BMD at the lumbar spine at 12 months. Secondary end points were the mean percentage change in BMD at the femoral neck and total hip and changes in bone turnover markers. Statistical comparison was performed using analysis of covariance. RESULTS: Of the 147 subjects enrolled in this study, 102 were randomly assigned into the minodronate (n = 36), denosumab (n = 36), and control (n = 30) groups. The percentage change in BMD at the lumbar spine was significantly improved in the minodronate (2.5%, p < 0.05) and denosumab groups (4.0%, p < 0.01) compared with that in the control group (- 0.1%). Denosumab increased BMD at the femoral neck and total hip at 12 months, whereas minodronate only increased BMD at the total hip compared with controls (all p < 0.05). The percentage change in bone turnover markers at 12 months was significantly lower in the minodronate and denosumab groups compared with that in the control group (both p < 0.01). CONCLUSION: Minodronate or denosumab can be used for preventing bone loss related to ADT in Asian patients with PCa.
There is still a lack of evidence that minodronate or denosumab prevents bone loss due to androgen deprivation therapy (ADT) in non-Western patients. This study showed that both drugs significantly improved lumbar spine and total hip bone mineral density in Asian men with prostate cancer who received ADT. INTRODUCTION: To evaluate whether monthly oral minodronate or semiannual subcutaneous injection of denosumab improves bone mineral density (BMD) in Asian men with prostate cancer (PCa) receiving ADT. METHODS: A multicenter, open-label, randomized, controlled study including patients with hormone-sensitive PCa without bone metastasis receiving ADT was performed. Patients were randomized (1:1:1) to minodronate, denosumab, or no agent control groups. The primary end point was the mean percentage change in BMD at the lumbar spine at 12 months. Secondary end points were the mean percentage change in BMD at the femoral neck and total hip and changes in bone turnover markers. Statistical comparison was performed using analysis of covariance. RESULTS: Of the 147 subjects enrolled in this study, 102 were randomly assigned into the minodronate (n = 36), denosumab (n = 36), and control (n = 30) groups. The percentage change in BMD at the lumbar spine was significantly improved in the minodronate (2.5%, p < 0.05) and denosumab groups (4.0%, p < 0.01) compared with that in the control group (- 0.1%). Denosumab increased BMD at the femoral neck and total hip at 12 months, whereas minodronate only increased BMD at the total hip compared with controls (all p < 0.05). The percentage change in bone turnover markers at 12 months was significantly lower in the minodronate and denosumab groups compared with that in the control group (both p < 0.01). CONCLUSION: Minodronate or denosumab can be used for preventing bone loss related to ADT in Asian patients with PCa.
Entities:
Keywords:
Androgen deprivation therapy; Bisphosphonate; Bone health; Prostate cancer; Receptor activator of nuclear factor-κB ligand
Authors: J P Brown; C Roux; P R Ho; M A Bolognese; J Hall; H G Bone; S Bonnick; J P van den Bergh; I Ferreira; P Dakin; R B Wagman; C Recknor Journal: Osteoporos Int Date: 2014-03-28 Impact factor: 4.507
Authors: Benoit Cadieux; Robert Coleman; Pegah Jafarinasabian; Allan Lipton; Robert Z Orlowski; Fred Saad; Giorgio V Scagliotti; Kazuyuki Shimizu; Alison Stopeck Journal: J Bone Oncol Date: 2022-02-07 Impact factor: 4.072